Premium
Combination of everolimus and tacrolimus: a potentially effective regimen for recalcitrant psoriasis
Author(s) -
Wei KaiChe,
Lai PingChin
Publication year - 2014
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12176
Subject(s) - medicine , psoriasis , everolimus , tacrolimus , regimen , sirolimus , refractory (planetary science) , calcineurin , dermatology , pi3k/akt/mtor pathway , pharmacology , transplantation , apoptosis , biochemistry , chemistry , physics , astrobiology
Severe forms of psoriasis that are refractory to conventional therapies are often difficult to manage. The mammalian target of rapamycin (m TOR ) inhibitors potentially have versatile effects toward putative psoriatic pathologic pathways. Therefore, m TOR inhibitors may offer a range of new therapeutic options for patients with psoriasis. We describe a 55‐year‐old male renal transplant patient with refractory psoriasis. We adjusted his antirejection regimen and put him on everolimus ( C ertican ® ; Novartis, Basel, Switzerland; a semisynthetic macrolide, belonging to the m TOR inhibitors family) with low‐dose tacrolimus. This combination regimen maintained his graft function and successfully controlled his psoriasis. His skin lesions never recurred in the next 18 months. To our knowledge, this is the first report showing that the combination of everolimus and tacrolimus could be used to treat recalcitrant psoriasis. The relative benefit–risk profiles of such therapies worth further investigation.